DCN Corp®

🔬 💊 𝗗𝗖𝗡 𝗖𝗼𝗿𝗽® | Nano-Tech for Equitable Innovation At DCN Corp®, we’re committed to transforming nano-tech into accessible and life-enhancing solutions. Our proprietary technology is validated to Technology Readiness Level 3 (TRL 3) and protected through an IP strategy. 🌐 What We Do: We believe we've developed a novel Surface Plasmon Resonance (SPR) process technology - translatable into next-gen diagnostic tool aiming to deliver real-time, quantifiable insights into biological conditions. This innovation will evolve into a scalable, handheld bio-kit supporting early detection and precision diagnostics. 🎯 Our Mission: To pioneer the development and understanding of nano-tech applications that can positively impact humanity. Through rigorous research and sound science, we aim to demonstrate how nano-tech, especially in healthcare can lead to life-changing innovations. 👁️ Our Vision: We all know someone affected by serious illness - cancer, cardiovascular disease, or other life-altering conditions. These diseases respond better to treatment when detected early and accurately categorised. Our vision is to create a handheld diagnostic bio-kit that supports this goal, aligning with future trends in at-home rapid diagnostics. 📖 This vision is supported by leading research including the Science journal by Crosby et al. (2022), “Early Detection of Cancer”. ⚙️ SPR Tool Capabilities:- ✅ Real-time diagnostic results ✅ Quantitative severity analysis ✅ Compatibility with Raman & Infrared instruments (desktop & handheld) 🤝 What We Need To bring this vision to life, we’re actively seeking:- 🔧 Technical collaborations 💰 Financial partnerships 🎯 Our next R&D milestone: applying nano-tech to plastic polymer substrates to increase bio-sensitivity. 💸 We’re currently raising a pre-seed round of £500k+ ($677K+). 📩 If you're an investor, scientist, or partner interested in shaping the future of diagnostics, request our Executive Summary today.